Clinical Predictors of Fluoroquinolone‐Resistant Escherichia coli in Transrectal Ultrasound‐Guided Prostate Biopsy: Insights for Tailored Prophylaxis
International Journal of Urology · 2025
DOI: 10.1111/iju.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Takatoshi Somoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Toho University Sakura Medical Center, Sakura, Japan. Hauptthemen laut MEDLINE: Fluoroquinolones, Escherichia coli, Escherichia coli Infections, Antibiotic Prophylaxis. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
To identify clinical predictors of fluoroquinolone‐resistant Escherichia coli colonization and evaluate their usefulness in guiding personalized antibiotic prophylaxis for patients undergoing transrectal ultrasound‐guided prostate biopsy.
Methods
A retrospective analysis was conducted on 539 patients who underwent biopsy between January 2015 and March 2023 at a high‐volume referral center. Clinical data, including demographic, biochemical, and pathological parameters, were extracted. Patients were stratified into high‐ and low‐risk groups based on the Japanese Urological Association's risk classification. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of fluoroquinolone‐resistant E. coli .
Results
Fluoroquinolone‐resistant E. coli was detected in 17.1% of patients. The prevalence increased significantly over time, from 14.1% in the earlier period (2015–2019) to 20.9% in the later period (2019–2023) ( p = 0.04). Multivariate analysis identified elevated C‐reactive protein greater than 0.09 mg/dL and the use of steroid or immunosuppressive therapy as independent predictors of fluoroquinolone‐resistant E. coli . In high‐risk patients, elevated HbA1c greater than 5.9% was also a significant predictor. Notably, patients with fluoroquinolone‐resistant flora had significantly lower rates of prostate cancer detection, particularly among low‐risk individuals (52.1% vs. 75.7%, p < 0.01).
Conclusions
Elevated C‐reactive protein and immunosuppressive therapy are strong clinical predictors of fluoroquinolone‐resistant E. coli colonization. These factors should be integrated into pre‐biopsy assessment to guide selective rectal swab testing and tailor prophylactic strategies, thereby enhancing patient safety and reducing antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
- Department of Hematology, Toho University Sakura Medical Center, Sakura, Japan.
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan.
- Department of Surgical Pathology, Toho University Sakura Medical Center, Sakura, Japan.
ORCID-Profile: Takanobu Utsumi, Hiroyoshi Suzuki
Zitieren
APA
Somoto, T., Utsumi, T., Ishitsuka, N., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., Oka, R., Endo, T., Kamiya, N., Shimizu, N., Hiruta, N., & Suzuki, H. (2025). Clinical Predictors of Fluoroquinolone‐Resistant Escherichia coli in Transrectal Ultrasound‐Guided Prostate Biopsy: Insights for Tailored Prophylaxis. International Journal of Urology. https://doi.org/10.1111/iju.70082
Vancouver
Somoto T, Utsumi T, Ishitsuka N, Noro T, Suzuki Y, Iijima S, et al. Clinical Predictors of Fluoroquinolone‐Resistant Escherichia coli in Transrectal Ultrasound‐Guided Prostate Biopsy: Insights for Tailored Prophylaxis. International Journal of Urology. 2025. doi:10.1111/iju.70082
BibTeX
@article{Somoto2025,
author = {Somoto, Takatoshi and Utsumi, Takanobu and Ishitsuka, Naoki and Noro, Takahide and Suzuki, Yuta and Iijima, Shota and Sugizaki, Yuka and Oka, Ryo and Endo, Takumi and Kamiya, Naoto and Shimizu, Naomi and Hiruta, Nobuyuki and Suzuki, Hiroyoshi},
title = {Clinical Predictors of Fluoroquinolone‐Resistant Escherichia coli in Transrectal Ultrasound‐Guided Prostate Biopsy: Insights for Tailored Prophylaxis},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70082}
}
EUVIMED